Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb;13(2):70-2.
doi: 10.1038/nrgastro.2015.227. Epub 2016 Jan 21.

HCV in 2015: Advances in hepatitis C research and treatment

Barbara Rehermann  1
Affiliations
Review

HCV in 2015: Advances in hepatitis C research and treatment

Barbara Rehermann. Nat Rev Gastroenterol Hepatol. 2016 Feb.

Abstract

In 2015, new treatment regimens were revealed that achieve >95% cure rates for all HCV genotypes. The HCV polymerase structure was solved in catalytically relevant HCV replication steps and in the context of nucleotide analogue inhibition. Moreover, HCV research taught us new links between innate antiviral responses, lipid metabolism and intracellular membrane formation.

PubMed Disclaimer

Conflict of interest statement

The author does not have any competing interests.

Figures

Figure 1.
Figure 1.
Patients cured of HCV infection. a) graph shows cured patients as percentage of all treated patients. b) Absolute number of patients in the USand worldwide who were cured by direct acting antivirals,. Of the 185 million people worldwide infected with HCV only a minority have been diagnosed. Black bars represent patients infected with HCV and orange bars represent cured patients. Cure is defined as achieving sustained virological response. IFN, interferon; PEG-IFN, pegylated interferon; RBV, ribavirin; DAA, direct acting antivirals.
See this image and copyright information in PMC

References

    1. Appleby TC et al. Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase. Science 347, 771–5 (2015). - PubMed
    1. Feld JJ et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015). - PubMed
    1. Foster GR et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015). - PubMed
    1. Curry MP et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015). - PubMed
    1. Asrani SK & Davis GL Impact of birth cohort screening for hepatitis C. Curr Gastroenterol Rep 16, 381 (2014). - PubMed